Bank of America lowered its price target for Hims & Hers Health to $30 from $32, maintaining a Neutral rating after the company's Q1 2026 results missed revenue and earnings expectations. The firm sees the need for a reset in market expectations due to challenges from transitioning U.S. weight loss treatments from compounded to branded GLP-1 drugs, which impacted revenue and led to restructuring charges. Despite the downgrade, other analysts remain divided, reflecting uncertainty about the company's valuation and strategic pivot. Investors are advised to be patient as the stock may need time to stabilize amid high valuation multiples and mixed growth signals.
Hims & Hers Health has been upgraded to a buy rating due to stronger-than-expected sales of its branded GLP-1 drug Wegovy, which shipped 125,000 units in six weeks. Management now expects over 100,000 monthly new weight-loss subscribers, restoring co...
Hims & Hers Health increased its full-year 2026 revenue guidance to $2.8-$3.0 billion despite reporting a quarterly EPS loss impacted by restructuring charges. The company showed strong subscriber growth nearing 2.6 million and high engagement with 9...
Shares of Hims & Hers Health dropped after JPMorgan lowered its price target from $35 to $33 following a mixed first-quarter report and a strategic shift from compounded to branded GLP-1 medications. Despite the cut, JPMorgan maintained an Overweight...
Hims & Hers shares fell about 14% in pre-market trading following a disappointing Q1 report, attributed to timing of the Novo Nordisk deal and tough year-over-year comparisons. Despite the initial drop, analysts see the Q2 guidance beat and raised fu...
Telehealth company Hims & Hers saw its stock fall 15.7% in premarket trading after reporting a first-quarter net loss of $92 million, nearly double last year's $50 million loss. Revenue rose 4% to $608 million, but average monthly revenue per subscri...
